BackIN8bio Overview

IN8bio Current Assets

Track IN8bio's current assets ($23M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$22.66M
↑ 78.09% YoYΔ $9.94M vs prior year quarter

Peer average

Loading

IN8bio Current Assets History

Loading

IN8bio vs. peers: Current Assets Comparison

Loading

IN8bio Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

IN8bio (INAB) FAQ

As of the most recent data (March 2026), INAB shows a current assets of $23M. That compares with $13M in the prior-year period — up 78.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, INAB's current assets is now $23M (was $13M) — a 78.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether IN8bio is outperforming or lagging.

Tracking INAB's current assets over time shows whether IN8bio is scaling, shrinking, or reshaping that part of the business. The current reading is $23M That compares with $13M in the prior-year period — up 78.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current assets page, Stockcircle has IN8bio's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current assets (currently $23M) with ownership activity and broader fundamentals.

IN8bio's current assets is $23M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.